Analyst Ratings For Galmed Pharmaceuticals (NASDAQ:GLMD)
Today, Galmed Pharmaceuticals (NASDAQ:GLMD) stock was downgraded by Maxim Group from Buy to Hold.
Some recent analyst ratings include
- 2/14/2018-Maxim Group was Downgraded by analysts at Maxim Group from a “Buy ” rating to a ” Hold” rating.
- 11/15/2017-Roth Capital initiated coverage with a Buy rating.
- 10/6/2017-Seaport Global Securities Reiterated Rating of Buy.
Recent Trading Activity for Galmed Pharmaceuticals (NASDAQ:GLMD)
Shares of Galmed Pharmaceuticals closed the previous trading session at 4.20 down -5.26 55.60% with 4.385000228881836 shares trading hands.